Vigabatrin
Overview
Vigabatrin is an antiepileptic drug used as an adjunctive therapy for patients with refractory complex partial seizures. It irreversibly inhibits the enzyme gamma-aminobutyric acid transaminase (GABA-T), leading to increased levels of GABA in the brain.
API suppliers (7)
Suppliers of Vigabatrin evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 6 of 7 suppliers.
5 of 7 hold a GMP certificate on record in the EU or UK registers
- Divis LaboratoriesIndia1 active DMF GMP on record
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- Hetero Drugs LimitedIndia1 active DMF GMP on record
- APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
- METROCHEM API PRIVATE LTDIndia1 active DMF
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia1 active DMF GMP on record
- SIONC PHARMACEUTICALS PVT LTD1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (21 approved US products), the latest listed US patent on Vigabatrin expires 8 Jun 2043. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Vigabatrin? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.